BRAF and thyroiditis: Dabrafenib is a potent selective small-molecule inhibitor of BRAF kinase that is orally bioavailable and FDA-approved for treating multiple cancers with activated BRAF (BRAF V600E or V600K mutations) such as melanoma, small cell lung carcinoma, thyroid, and biliary tract cancers (15–18).